Forteo Related Published Studies
Well-designed clinical trials related to Forteo (Teriparatide)
[Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis]. [Article in Japanese] [2012]
Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis. [2011.09.21]
Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy. [2011.09.21]
Short-term teriparatide delivery and osseointegration: a clinical feasibility study. [2011.08]
Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis. [2011.05.01]
The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. [2011.05]
PINP as an aid for monitoring patients treated with teriparatide. [2011.04.01]
Time-dependent changes in skeletal response to teriparatide: escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women. [2011.04.01]
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. [2011.03]
Teriparatide and osseous regeneration in the oral cavity. [2010.12.16]
Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. [2010.12]
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [(1-34)rhPTH] in postmenopausal osteoporosis. [2010.09.02]
Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS. [2010.08]
Teriparatide improves early callus formation in distal radial fractures. [2010.04]
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. [2010.04]
Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. [2010.04]
Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. [2010.04]
Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. [2010.02]
Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. [2010.01]
Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. [2010.01]
Effects of teriparatide on bone mineral density and bone turnover markers in
Japanese subjects with osteoporosis at high risk of fracture in a 24-month
clinical study: 12-month, randomized, placebo-controlled, double-blind and
12-month open-label phases. [2010]
Bone formation markers in patients with glucocorticoid-induced osteoporosis
treated with teriparatide or alendronate. [2010]
Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. [2009.12]
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. [2009.11]
Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. [2009.10]
Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. [2009.08]
Effects of teriparatide retreatment in osteoporotic men and women. [2009.07]
Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials. [2009.06]
Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. [2009.06]
Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. [2009.06]
Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. [2009.06]
Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. [2009.04]
Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). [2009.04]
No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. [2009.04]
Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts. [2009.01]
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. [2008.10]
No difference between strontium ranelate and calcium / vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. [2008.07.07]
Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. [2008.04]
Serum Osteoprotegerin and RANKL are not Specifically Altered in Women with Postmenopausal Osteoporosis Treated with Teriparatide or Risedronate: A Randomized, Controlled Trial. [2008.02.15]
Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study. [2008]
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. [2007.11.15]
Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. [2007.09]
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. [2007.01]
Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. [2006.11]
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. [2006.11]
Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. [2006.08]
Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. [2006.08]
Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. [2006.06]
A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. [2006.05]
Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. [2006.05]
Reduced risk of back pain following teriparatide treatment: a meta-analysis. [2006.02]
Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. [2006]
Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. [2006]
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. [2005.11]
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. [2005.09]
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. [2005.08.08]
Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. [2005.08]
Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. [2005.08]
The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. [2005.07]
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. [2005.07]
Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. [2005.07]
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. [2005.06]
Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. [2005.06]
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. [2005.05]
Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. [2005.03]
Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. [2004.12]
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. [2004.10.11]
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. [2003.11]
The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women. [2003.07]
Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin. [2003.01]
The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. [2003.01]
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. [2003.01]
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. [2002.10]
Well-designed clinical trials possibly related to Forteo (Teriparatide)
Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. [2011.11.02]
Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. [2011.11.01]
The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. [2011.08]
The impact of vitamin D status on periodontal surgery outcomes. [2011.08]
Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. [2011.01]
[Assessment of vertebral fractures on radiographs and the effects of drug therapy
on vertebral fractures]. [Article in Japanese] [2011]
Antifracture efficacy of currently available therapies for postmenopausal
osteoporosis. [2011]
Phosphate and carbonate salts of calcium support robust bone building in osteoporosis. [2010.07]
Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. [2008.09]
Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study. [2006.10]
Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study. [2006.01]
Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). [2005.12]
[Treatment of osteoporosis with parathyroid hormone: evidence and perspective] [2005.04]
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. [2003.09.25]
Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. [2003.09]
Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. [2003.01]
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. [2001.05.10]
Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. [2001.02]
Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur. [2001]
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. [2000.06]
Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. [2000]
Effects of gonadal suppression on the regulation of parathyroid hormone and 1,25-dihydroxyvitamin D secretion in women. [1999.06]
Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. [1999.04]
Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. [1999]
Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. [1998.10.15]
A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. [1998.10]
Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. [1998.09.23]
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. [1997.08.23]
|